Kemps-Polanco Reshema 4

What Happened
Reshema Kemps-Polanco, a director of Charles River Laboratories (CRL), was granted a total of 1,973 restricted stock units (RSUs) on May 8, 2026. The grants are reported as two acquisitions: 1,438 RSUs at $177.62 each (value $255,418) and 535 RSUs at $177.62 each (value $95,027), for a combined value of approximately $350,445. This was an award/grant transaction (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-08; filing date (Form 4): 2026-05-11 (timely filed).
• Grants: 1,438 RSUs @ $177.62 = $255,418 (F1); 535 RSUs @ $177.62 = $95,027 (F2).
• Total RSUs granted: 1,973; total reported value ≈ $350,445.
• Vesting (F1/F2): RSUs vest upon the earlier of May 8, 2027, or the business day prior to the company’s next annual shareholders’ meeting.
• Note on F2: the 535-RSU grant was issued in lieu of director service fees for the term beginning May 5, 2026.
• Shares owned after transaction: not specified in the filing.
• Transaction type: Award/Grant (A). This is not a sale or purchase of existing shares.

Context
RSU grants to directors are common compensation and do not necessarily signal the director’s immediate market view—these units vest in the future if conditions are met. Because these were awards (not open-market buys), they reflect compensation structure rather than a direct cash investment by the insider.